Clinical trial
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal…
NCT00481065 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00481065 |
|---|---|
| Title | Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects |
| Official title | A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pandemic, Avian Influenza |
| Intervention type | Biological |
| Interventions | MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a |
| Enrollment | 405 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 1, 2007 |
| Last update posted | Feb 3, 2014 |
| Countries | Colombia |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: